SCHEMBL19970748

SCHEMBL19970748

O=C(c1ccc2[nH]c(-c3ccccn3)nc2c1)N1CCN(Cc2cccc(OC(F)(F)F)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.51
RUNX1 Q01196 2/20 0.49
CBFB Q13951 1/20 0.49
LMNA P02545 3/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 2/20 0.47
KRAS P01116 1/20 0.47
MGLL Q99685 1/20 0.46
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
KCNK3 O14649 1/20 0.45
KCNK9 Q9NPC2 1/20 0.45
SLC6A7 Q99884 1/20 0.44
RECQL P46063 1/20 0.44
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970749 0.94 RUNX1 (0.56) STAT3RUNX1CBFBLMNAKDM4E
SCHEMBL19970847 0.92 RUNX1 (0.51) STAT3RUNX1CBFBLMNAKDM4E
SCHEMBL19970750 0.89 MEN1 (0.53) STAT3RUNX1LMNAKDM4EALDH1A1
SCHEMBL19970757 0.89 CBFB (0.58) RUNX1CBFBLMNAKDM4EALDH1A1
SCHEMBL19970849 0.86 RUNX1 (0.58) STAT3RUNX1CBFBMAPK14ACACB
SCHEMBL19970864 0.85 STAT3 (0.51) STAT3LMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL19970768 0.85 SIGMAR1 (0.55) STAT3CBFBMAPK14
SCHEMBL19970758 0.83 CBFB (0.66) RUNX1CBFBNPC1
SCHEMBL19970751 0.82 BCHE (0.55) STAT3RUNX1LMNAKDM4EALDH1A1
SCHEMBL19970786 0.82 STAT3 (0.48) STAT3LMNAKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS STAT3 2805/4885RUNX1 2083/4885CBFB 3631/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS STAT3 2805/4885RUNX1 2083/4885CBFB 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.